Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents-Reference-Cited by-同舟云学术

Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents

Published:2022-12 Issue: Volume:12 Page:100211
ISSN:2590-1362
Container-title:Vaccine: X
language:en
Short-container-title:Vaccine: X

Author:

Puthanakit Thanyawee,Nantanee Rapisa,Jaru-Ampornpan Peera,Chantasrisawad Napaporn,Sophonphan Jiratchaya,Meepuksom Thutsanun,Jupimai Thidarat,Sodsai Pimpayao,Anugulruengkitt Suvaporn,Hirankarn Nattiya

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference36 articles.

1. SARS-CoV-2 vaccines in development;Krammer;Nature,2020

2. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents;Frenck;N Engl J Med,2021

3. Wanlapakorn N, Yorsaeng R, Phowatthanasathian H, Suntronwong N, Kanokudom S, Sudhinaraset N, et al. Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine. medRxiv 2021:2021.11.20.21266644. https://doi.org/10.1101/2021.11.20.21266644.

4. Anti-SARS-CoV-2 IgG antibody levels among Thai healthcare providers receiving homologous and heterologous COVID-19 vaccination regimens;Kittikraisak;Influenza Other Respir Viruses,2022

5. Dynamics of Neutralizing Antibody and T-Cell Responses to SARS-CoV-2 and Variants of Concern after Primary Immunization with CoronaVac and Booster with BNT162b2 or ChAdOx1 in Health Care Workers;Jantarabenjakul;Vaccines,2022

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVac;Vaccines;2024-08-15

2. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up;International Immunopharmacology;2024-06

3. Safety and immunogenicity of COReNAPCIN^®, a SARS-CoV-2 mRNA vaccine; a randomized, double-blind, placebo-controlled phase 1 clinical trial;2023-11-02

4. Immunogenicity of coronavirus disease 2019 vaccines in children: A review with ChatGPT;Pediatric Discovery;2023-06

5. Comparison of the reactogenicity and immunogenicity between two‐dose mRNA COVID‐19 vaccine and inactivated COVID‐19 vaccine followed by an mRNA vaccine in children aged 5−11 years;Journal of Medical Virology;2023-04-27